How Do Peptides Work? The Science Explained

You’ve probably heard that peptides are “signaling molecules” or “chemical messengers.” That’s accurate but vague — like saying a phone works by “sending signals.” The real question is how a chain of amino acids can tell your body to burn fat, heal a torn tendon, or release growth hormone.

Understanding the mechanism matters if you’re considering peptide therapy. It explains why some peptides need to be injected while others work orally. Why effects take days or weeks to appear. And why the same peptide can produce different results at different doses. This article breaks down the science without requiring a biochemistry degree.

Key Takeaways

• Peptides work by binding to specific receptors on cell surfaces, triggering internal signaling cascades that change cell behavior [1]
• Different peptides target different receptor types — GLP-1 peptides hit incretin receptors, GH peptides activate ghrelin or GHRH receptors, and healing peptides interact with growth factor pathways [2]
• Most therapeutic peptides mimic natural signaling molecules your body already produces, but in higher or more sustained concentrations [3]
• The route of administration affects how peptides work — injections bypass digestion, while oral peptides need special formulations to survive stomach acid [4]

Table of Contents

1. Peptides 101: The Basics
2. Receptor Binding: The Lock and Key
3. Signal Transduction: What Happens After Binding
4. How GLP-1 Peptides Work
5. How Growth Hormone Peptides Work
6. How Healing Peptides Work
7. Why Administration Route Matters
8. Half-Life and Dosing Frequency
9. FAQ
10. Sources

Peptides 101: The Basics

Peptides are short chains of amino acids — typically between 2 and 50 amino acids long. Your body produces hundreds of them naturally. Insulin (51 amino acids) is technically a peptide. So is oxytocin (9 amino acids). So are the endorphins that give you a runner’s high [1].

What separates peptides from proteins is size. Once a chain exceeds roughly 50 amino acids, it’s generally classified as a protein. But the functional distinction matters more: peptides tend to act as signaling molecules, while proteins often serve structural or enzymatic roles.

The peptides used in therapy — whether that’s semaglutide for weight loss, BPC-157 for injury repair, or CJC-1295 for growth hormone release — are either synthetic copies of natural peptides or modified versions designed to last longer in the body. You can see the full range of compounds in our list of peptides guide.

Receptor Binding: The Lock and Key

The fundamental mechanism of peptide action is receptor binding. Think of it this way: your cells are covered in receptor proteins — thousands of them, each with a specific shape. Peptides are the keys that fit into these locks [2].

When a peptide binds to its receptor, the receptor changes shape. That shape change triggers a chain reaction inside the cell. The specifics of that reaction depend on which receptor was activated and what type of cell it sits on.

This is why different peptides do different things. Semaglutide binds to GLP-1 receptors, which are concentrated in the pancreas, brain, and gut. BPC-157 interacts with growth factor receptors found in connective tissue, blood vessels, and the GI tract. CJC-1295 targets GHRH receptors on pituitary cells. Same basic mechanism — receptor binding — but completely different outcomes because the receptors and target cells differ.

Selectivity and Specificity

One reason peptides are attractive therapeutically: they tend to be highly selective. A peptide designed for the GLP-1 receptor won’t accidentally activate growth hormone receptors. This selectivity means fewer off-target effects compared to small molecule drugs that can interact with multiple receptor types [5].

That said, no molecule is perfectly selective. Some peptides interact with more than one receptor type at different affinities. Tirzepatide, for example, activates both GLP-1 and GIP receptors — and this dual action is precisely why it appears to produce stronger weight loss effects than semaglutide alone [6].

Signal Transduction: What Happens After Binding

Receptor binding is just the first domino. What follows is a process called signal transduction — a cascade of molecular events inside the cell that ultimately changes its behavior [7].

Most peptide receptors fall into a category called G protein-coupled receptors (GPCRs). These are the largest family of cell surface receptors in the human body, and they’re responsible for an enormous range of biological processes — from vision to immune function to hormone regulation.

Here’s the simplified version of what happens:

1. Peptide binds to receptor on the cell surface
2. Receptor activates a G protein on the inside of the cell membrane
3. G protein triggers second messengers — molecules like cyclic AMP (cAMP), calcium ions, or inositol phosphates
4. Second messengers activate protein kinases — enzymes that switch other proteins on or off
5. Target proteins change cell behavior — producing new proteins, releasing stored hormones, or altering gene expression

This cascade is why peptide effects aren’t instantaneous. The signaling chain takes time to propagate, and many downstream effects involve changes in gene expression — your cells literally making new proteins. That’s why growth hormone peptide benefits accumulate over weeks, not hours.

How GLP-1 Peptides Work

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It does three things: stimulates insulin release, slows stomach emptying, and signals fullness to your brain [8].

The problem? Natural GLP-1 has a half-life of about 2 minutes. Your body’s DPP-4 enzymes chew it up almost immediately.

Therapeutic GLP-1 peptides like semaglutide solve this by modifying the amino acid structure to resist DPP-4 degradation. Semaglutide also attaches to albumin (a blood protein), which further extends its half-life to roughly 7 days — enabling once-weekly dosing [9].

Once bound to GLP-1 receptors, the effects play out across multiple organ systems:

• Pancreas: Increases insulin secretion (only when blood sugar is elevated — this is why GLP-1s have low hypoglycemia risk) [8]
• Stomach: Delays gastric emptying, keeping you feeling full longer
• Brain (hypothalamus): Reduces appetite signaling, decreases food reward pathways
• Brain (nausea centers): Activates the area postrema — which is also why nausea is the most common side effect

The weight loss effect isn’t just about eating less. Emerging research suggests GLP-1 receptor activation may also influence fat cell metabolism and reduce systemic inflammation [10]. For more on how these peptides drive fat loss specifically, see our guide on peptides for weight loss.

How Growth Hormone Peptides Work

Growth hormone (GH) secretagogues don’t contain growth hormone. Instead, they stimulate your pituitary gland to produce and release more of its own GH. This distinction matters because it preserves the body’s natural pulsatile GH release pattern rather than flooding the system with exogenous hormone [3].

Two main receptor pathways are involved:

GHRH Receptor Pathway

CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on somatotroph cells in the anterior pituitary. This activates the cAMP signaling cascade, which triggers both the release of stored GH and the production of new GH [11].

The “DAC” (Drug Affinity Complex) version of CJC-1295 binds to albumin, extending its half-life from minutes to 6-8 days. A 2006 study in healthy adults showed that a single dose increased GH levels 2-10 fold, with sustained IGF-1 elevation for 6-14 days [11].

Ghrelin Receptor Pathway

Ipamorelin is a growth hormone secretagogue that mimics ghrelin — the “hunger hormone” — at the GHS-R1a receptor. But unlike ghrelin itself, ipamorelin is highly selective. It stimulates GH release without significantly increasing cortisol, prolactin, or ACTH [12].

This selectivity is why the CJC-1295/ipamorelin combination is popular: CJC-1295 amplifies GH production through one pathway while ipamorelin triggers GH release through another. The two pathways are synergistic — together they produce a larger GH pulse than either alone [3].

How Healing Peptides Work

Healing peptides like BPC-157 and GHK-Cu operate through different mechanisms than the hormone-targeting peptides above. Their actions center on tissue repair pathways — modulating inflammation, promoting blood vessel formation, and activating growth factors.

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid fragment derived from a protective protein found in human gastric juice. Its mechanism isn’t fully mapped, but research points to several pathways [13]:

• Nitric oxide system modulation — BPC-157 appears to interact with the NO system, which regulates blood vessel dilation and blood flow to injured tissues
• Growth factor upregulation — animal studies show it increases expression of VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor), promoting angiogenesis and tissue regeneration
• FAK-paxillin pathway activation — this intracellular signaling cascade is involved in cell migration and wound closure
• Gut-brain axis interaction — BPC-157 may modulate dopamine and serotonin systems, which could explain reported effects on mood and cognition in animal models

GHK-Cu

GHK-Cu (copper peptide) is a naturally occurring tripeptide that declines with age. Its mechanism is remarkably broad because it acts primarily through gene expression changes — it’s been shown to modulate over 4,000 genes in human tissue [14].

Key pathways include:

• Copper delivery — copper is required for numerous enzymes involved in tissue repair, collagen synthesis, and antioxidant defense
• TGF-beta signaling — promotes wound healing and tissue remodeling
• Metalloproteinase regulation — balances tissue breakdown and rebuilding
• Anti-inflammatory gene activation — reduces inflammatory cytokine expression

Why Administration Route Matters

How a peptide enters your body changes how it works — and whether it works at all.

The Digestion Problem

Most peptides are chains of amino acids held together by peptide bonds. Your stomach and small intestine contain enzymes (proteases and peptidases) whose entire job is breaking these bonds apart. Swallow most peptides and they’ll be digested into individual amino acids before reaching your bloodstream — functionally useless as signaling molecules [4].

This is why most therapeutic peptides are injected subcutaneously. The peptide enters the tissue just below the skin, absorbs into capillaries, and reaches systemic circulation intact.

Exceptions to the Rule

Some peptides are specifically formulated for oral delivery. Oral semaglutide (Rybelsus) uses a permeation enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) that temporarily increases gastric pH and helps the peptide absorb through the stomach lining [15]. Even so, oral bioavailability is only about 1% — meaning you need a much larger dose orally than you would with injection.

BPC-157 is an interesting case. Because it’s derived from gastric juice proteins, some evidence suggests it retains activity when taken orally — at least for GI-related effects. Oral BPC-157 has shown effects on gut healing in animal models, though systemic effects (joints, tendons) likely require injection [13].

Topical Application

Some peptides like GHK-Cu work topically because skin cells have the relevant receptors on their surface. The peptide doesn’t need to reach systemic circulation — it acts locally on the cells it contacts. This is why copper peptide serums can promote skin repair without injection [14].

Half-Life and Dosing Frequency

A peptide’s half-life — how long it takes for half the dose to be eliminated — determines how often you need to take it. Natural peptides tend to have very short half-lives because the body is designed to rapidly clear signaling molecules once they’ve delivered their message.

Therapeutic modifications extend half-life dramatically:

Peptide	Natural Half-Life	Modified Half-Life	Dosing Frequency
GLP-1 (natural)	~2 minutes	—	—
Semaglutide	—	~7 days	Weekly
Tirzepatide	—	~5 days	Weekly
CJC-1295 (no DAC)	~30 minutes	—	2-3x daily
CJC-1295 DAC	—	~6-8 days	Weekly
Ipamorelin	—	~2 hours	1-3x daily
BPC-157	—	~4 hours (estimated)	1-2x daily

The engineering strategies used to extend half-life include fatty acid acylation (semaglutide), albumin binding (CJC-1295 DAC), PEGylation, and amino acid substitution to resist enzymatic degradation [9].

FAQ

How long does it take for peptides to start working?▼

It depends on the peptide and the effect you’re measuring. GLP-1 peptides reduce appetite within the first week, but meaningful weight loss typically takes 8-12 weeks to become noticeable [8]. Growth hormone peptides may produce better sleep within the first week, but body composition changes require 3-6 months. Healing peptides like BPC-157 are often reported to produce noticeable effects on pain and healing within 1-2 weeks.

Do peptides build up in your system?▼

Peptides with long half-lives (semaglutide, CJC-1295 DAC) do reach steady-state concentrations over several doses — meaning each dose adds to the previous one until levels plateau. This is why dose titration matters and why side effects often appear during early weeks.

Can your body become resistant to peptides?▼

Receptor desensitization is a real phenomenon. With prolonged, continuous stimulation, cells can downregulate receptors — reducing the response over time. This is why some GH peptide protocols use cycling (5 days on, 2 off) rather than continuous daily dosing [3]. GLP-1 receptor agonists appear less prone to this because of their intermittent dosing schedule.

Are synthetic peptides the same as natural ones?▼

Synthetic therapeutic peptides are usually based on natural peptides but modified for stability and potency. Semaglutide, for example, is 94% identical to human GLP-1 but has key amino acid substitutions that prevent enzymatic breakdown [9]. The modifications change pharmacokinetics (how the drug moves through your body) without changing the fundamental mechanism of action.

Why do some peptides need to be injected?▼

Most peptides are digested if taken orally — stomach acid and digestive enzymes break the amino acid chain into fragments that can’t activate receptors. Subcutaneous injection delivers the intact peptide directly into tissue where it can absorb into the bloodstream. Some peptides (oral semaglutide, BPC-157 for gut effects) have workarounds, but injection remains the most reliable delivery method for systemic effects [4].

Sources

1. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. DOI: 10.1016/j.drudis.2014.10.003

2. Davenport AP, et al. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020;19(6):389-413. DOI: 10.1038/s41573-020-0062-z

3. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. DOI: 10.1210/jc.2005-1536

4. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. DOI: 10.1038/s41573-019-0053-0

5. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707. DOI: 10.1016/j.bmc.2017.06.052

6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038

7. Weis WI, Kobilka BK. The molecular basis of G protein-coupled receptor activation. Annu Rev Biochem. 2018;87:897-919.

8. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001

9. Lau J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. DOI: 10.1021/acs.jmedchem.5b00726

10. Beiroa D, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63(10):3346-3358.

11. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.

12. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.

13. Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865.

14. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. DOI: 10.3390/ijms19071987

15. Buckley ST, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.